Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine and bupropion

doi:10.21203/rs.3.rs-4699654/v1

Download PDF

Short Report

Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine and bupropion

https://doi.org/10.21203/rs.3.rs-4699654/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Purpose

This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT.

Methods

43 patients (70.7 ± 8.6y, 44% female) with [¹²³I]FP-CIT-SPECT under venlafaxine (n = 26, 37.5-225mg/d), bupropion (n = 16, 150 or 300mg/d) or both (n = 1) were included retrospectively. The striatal specific [¹²³I]FP-CIT binding ratio (SBR), its left-right asymmetry and the putamen-to-caudate ratio were transformed to z-scores and submitted to a cluster analysis for data-driven categorization.

Results

Two clusters were identified. The first cluster (37% cases) showed a Parkinson’s disease (PD)-like pattern: median striatal SBR/asymmetry/putamen-to-caudate z-score − 4.5/4.9/-3.8. The second cluster (63%) showed symmetric reduction with normal intra-striatal gradient: median striatal SBR/asymmetry/putamen-to-caudate z-score − 2.7/0.4/0.2. Patients with follow-up clinical reference diagnoses of neurodegenerative (n = 7) and non-neurodegenerative (n = 16) parkinsonism fell exclusively into the former or the latter cluster, respectively (p < 0.001).

Conclusion

Venlafaxine and bupropion cause uniform reduction of the striatal [¹²³I]FP-CIT SBR that can be distinguished from PD-like reductions.

Dopamine transporter

[123I]FP-CIT

Drug interaction

Venlafaxine

Bupropion

Depression is a major comorbidity in Parkinson’s disease [1]. Thus, a relevant proportion of patients referred to dopamine transporter (DAT)-SPECT with N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-I-123-iodophenyl)nortropane ([¹²³I]FP-CIT) receives antidepressants including venlafaxine and bupropion.

There is a relative lack of studies on the impact of the latter antidepressants on [¹²³I]FP-CIT-SPECT [2–6]. As a consequence, current practice guidelines are somewhat inconsistent regarding the necessity of their withdrawal before [¹²³I]FP-CIT-SPECT. The joint EANM/SNMMI guideline recommends withdrawal of bupropion but not venlafaxine prior to [¹²³I]FP-CIT-SPECT [7], whereas the German guideline recommends to discontinue both, venlafaxine and bupropion [8]. These recommendations and their discrepancy are of high clinical relevance, as even short-term withdrawal of antidepressants can be critical in severely depressed patients. Particularly, withdrawal of venlafaxine may cause several somatic as well as severe (neuro)psychiatric symptoms [9].

This retrospective study examined the impact of venlafaxine and bupropion on the utility of [¹²³I]FP-CIT-SPECT to detect nigrostriatal degeneration.

Patients

The databases of the University Medical Centers of Freiburg and Hamburg were searched for clinical [¹²³I]FP-CIT-SPECT performed on persistent venlafaxine or bupropion treatment. Patients who had withdrawn the drug in preparation of [¹²³I]FP-CIT-SPECT were excluded, independent of the duration of the withdrawal. Patients who skipped only the single dose on the morning of the DAT-SPECT examination were included. There were no further eligibility criteria. This resulted in the inclusion of 43 patients (70.7 ± 8.6y, 44% female): 26 under venlafaxine (37.5-225mg/d), 16 under bupropion (150 or 300mg/d), one patient under both (112.5/150mg/d venlafaxine/bupropion).

A reference diagnosis based on clinical follow-up and/or FDG-PET and/or repeated [¹²³I]FP-CIT-SPECT after drug withdrawal was available in 24 patients: neurodegenerative/non-neurodegenerative parkinsonism (with/without nigrostriatal degeneration) in 8/16 (33/67%) patients.

Demographical and clinical data are given in Table 1.

Table 1

Demographical and clinical data. Age and drug dose are given as mean ± standard deviation (range).
	All	Venlafaxine	Bupropion	Both
Number of patients	43	26	16	1
Age	70.7 ± 8.6 (52–89)	72.7 ± 8.3 (52–89)	68.3 ± 8.1 (55–83)	57.8
Sex (% female)	44	54	25
Collimator (% LEHR)	51	27	87	100
Venlafaxine dose (mg/d)	115 ± 66 (37.5–225) N = 27	115 ± 67 (37.5–225)		112.5
Bupropion dose (mg/d)	259 ± 70 (150 or 300) N = 11		270 ± 63 (150 or 300) N = 10	150
Reference diagnosis (non-neurodegenerative/neurodegenerative/ not available)	16/8/19	4/5/17	11/3/2	1/0/0

SPECT imaging

DAT-SPECT was performed after intravenous injection of about 180 MBq [¹²³I]FP-CIT on a triple-head camera equipped with multiple-pinhole collimators [10] (n = 21) or on a double- or triple-head camera equipped with parallel-hole low-energy-high-resolution (LEHR) collimators (n = 22).

The multiple-pinhole projection data were reconstructed with the Monte Carlo photon simulation engine and iterative one-step-late maximum-a-posteriori expectation-maximization implemented in the camera software (24 iterations, 2 subsets) [10]. Chang’s method was used for attenuation correction.

The LEHR projection data were reconstructed using iterative ordered-subsets-expectation-maximization with attenuation and simulation-based scatter correction as well as collimator-detector response modelling implemented in the Hybrid Recon-Neurology tool of the Hermes SMART workstation v1.6 (5 iterations, 15/16 subsets for 120/128 views, 7mm gaussian postfiltering).

Semi-quantitative analyses

Semi-quantitative analyses were performed as described previously [10]. In brief, individual [¹²³I]FP-CIT-SPECT images were spatially normalized to the Montreal Neurological Institute space using the Normalize tool of the Statistical Parametric Mapping software package (SPM12) and a set of custom target [¹²³I]FP-CIT-SPECT images (representative of normal striatal signal and different levels of PD-like reductions). Semi-quantitative distribution volume ratio (DVR) images were obtained by voxelwise scaling to the individual 75th percentile of the voxel intensity in a reference region comprising the whole brain without striata, thalamus, medial temporal lobe, brainstem, cerebellum, and ventricles.

The unilateral [¹²³I]FP-CIT specific binding ratio (SBR) of left and right caudate, putamen and whole striatum was obtained by hottest voxels analysis of the spatially normalized DVR image using large unilateral masks. The number of hottest voxels to compute the average DVR was fixed to 5, 10 and 15ml, in line with the volumes of unilateral caudate, putamen and striatum in healthy subjects. The SBR of left and right caudate, putamen and striatum were obtained as SBR = DVR–1. Mean striatum SBR and putamen-to-caudate ratio were obtained by averaging the respective measures of both hemispheres. The asymmetry of the striatum SBR was computed as asymmetry[%] = 200*abs(left-right)/(left + right).

In order to eliminate systematic differences between multiple-pinhole and LEHR data, each of the aforementioned semi-quantitative measures was transformed to z-scores relative to the corresponding mean and standard deviation in a normative reference database. This was performed separately for multiple-pinhole and LEHR data. Both normative databases were built from consecutive clinical [¹²³I]FP-CIT-SPECT without any eligibility criteria except that the images had been interpreted as normal. Image reconstruction, preprocessing and semi-quantitative analyses in the normative databases were performed exactly as in the patients under venlafaxine and/or bupropion. The MPH normative database comprised 39 DAT-SPECT (mean patient age 68.0 ± 15.0y, 51% female), the LEHR normative database comprised 49 DAT-SPECT (68.3 ± 10.9y, 53% female). Neither normative database differed from the corresponding patients under venlafaxine and/or bupropion regarding age (p > 0.249) or sex (p > 0.412).

Statistical analysis

For data-driven categorization of the [¹²³I]FP-CIT-SPECT, a two-step cluster analysis was performed on the whole sample (n = 43) with the three z-scores as independent variables (clustering criterion: Schwarz’s Bayesian, distance measure: log-likelihood). The number of clusters was not fixed.

A 2x2 contingency table and the chi-squared test were used to test the clustering for an association with the reference diagnosis.

The mean striatum SBR z-score was tested for correlation with the drug dose using the non-parametric Spearman rank-order test. This was done separately for venlafaxine and bupropion and separately in each cluster from the cluster analysis.

Statistical analyses were performed with IBM SPSS statistics (version 29). All p-values are given two-sided. Statistical significance was assumed if p < 0.05.

The distribution of the striatal SBR among the 43 patients with [¹²³I]FP-CIT-SPECT under venlafaxine, bupropion or both is shown in Fig. 1. Thirty-five (81%) patients showed moderate or more severe reduction of the striatal signal (striatum SBR z-score < -2), 5 (12%) patients showed mild reduction (-1 > z-score≥-2).

The data-driven cluster analysis identified two clusters of good quality (Silhouette measure > 0.5) and without outliers. The first cluster comprised 16 cases (37%) and was characterized by a PD-like pattern: striatal binding was markedly reduced (median striatal SBR z-score: -4.5, [interquartile range: -5.8,-3.7]), showed high hemispheric asymmetry (z-score: 4.9 [1.9,9.0]) and a steep rostro-caudal gradient (median putamen-to-caudate z-score: -3.8 [-6.8,-2.0]). This cluster is denoted as “PD-like” cluster. The remaining 27 cases (63%) were included in the second cluster characterized by less pronounced, though still notable reduction of striatal binding (median SBR z-score: -2.7 [-3.1,-1.8]). Striatal binding was symmetric (median 0.4, interquartile range [-0.8,1.5]) and showed a normal rostro-caudal gradient (0.2 [-0.6,1.1]) (Fig. 2). This cluster is denoted as “uniform reduction” cluster. The automatic categorization of the multiple-pinhole images is summarized in Fig. 3.

All patients with a reference diagnosis of neurodegenerative parkinsonism (n = 8) were automatically categorized into the PD-like cluster, all patients with follow-up diagnosis of non-neurodegenerative parkinsonism (n = 16) were automatically categorized into the uniform reduction cluster (chi-squared p < 0.001).

The test for correlation between the mean striatum SBR and the drug dose in the uniform reduction cluster did not reveal a significant effect, neither in the patients under venlafaxine (n = 13, rho=-0.165, p = 0.589, Fig. 4a) nor in the patients under bupropion (n = 9, rho=--0.311, p = 0.416, Fig. 4b).

Repeat [¹²³I]FP-CIT-SPECT after withdrawal of bupropion or venlafaxine are shown in Supplementary Fig. 1.

The findings of this study are as follows. First, persistent treatment with typical doses of venlafaxine or bupropion is associated with a reduction of the striatal [¹²³I]FP-CIT SBR that can be similar in magnitude to the reduction caused by nigrostriatal degeneration.

Second, venlafaxine-/bupropion-induced reduction of the [¹²³I]FP-CIT SBR is rather uniform throughout both striata, that is, left-right symmetric and without PD-like rostro-caudal gradient. As a consequence, discrimination between venlafaxine-/bupropion-induced reduction and nigrostriatal degeneration is feasible (e.g., by using the cluster model or simple visual inspection, Fig. 3). Critical consideration is required in patients suspected to be at an early stage of dementia with Lewy bodies or an atypical neurodegenerative parkinsonian syndrome, since these might be associated with more uniform nigrostriatal degeneration. In such cases, drug withdrawal (if clinically justifiable) or study repetition after withdrawal (in case of questionable studies without withdrawal) is advisable. Uniform reduction of the striatal signal has also been observed by Hsiao and co-workers performing DAT-SPECT with ^99mTc-TRODAT-1 before and after 8 weeks of bupropion treatment in 23 patients with major depression (without parkinsonism) [5].

Third, the uniform reduction of the striatal [¹²³I]FP-CIT SBR caused by typical doses is similar for venlafaxine and bupropion. A recent systematic review of the potential effects of medications and drugs of abuse on [¹²³I]FP-CIT-SPECT concluded that bupropion treatment causes a 14–25% decrease of striatal [¹²³I]FP-CIT binding and recommended discontinuing bupropion for 5 days [2]. The same review did not find sufficient evidence to recommend withdrawal of venlafaxine [2], mainly based on a prospective study in 8 healthy controls showing 10.7 ± 3.0% increase of the striatal [¹²³I]β-CIT SBR after 4 days with 75mg followed by 5 days with 150mg venlafaxine [3]. However, there is a report of a false positive DAT-SPECT under 225mg venlafaxine, which was resolved by a repeat scan after venlafaxine withdrawal [4]. The current study clearly supports this case report and suggests that venlafaxine treatment causes a reduction of the striatal [¹²³I]FP-CIT SBR similar to bupropion. This finding is surprising given that the affinity for the DAT is at least one order of magnitude higher for bupropion compared with venlafaxine (K_D=520 versus 9300nM [11]). Thus, non-specific or serotonin transporter-mediated effects of venlafaxine on [¹²³I]FP-CIT uptake appear more likely than direct DAT blocking. Finally, we consider it highly unlikely that the consistent venlafaxine-/bupropion-associated uniform reduction observed in non-PD patients is an effect of depression, since depression-related DAT changes are at most very small [12].

Fourth, no significant relationship between the dose and the striatal SBR was observed, neither for venlafaxine nor for bupropion. This might be explained by some selection bias: assuming that the antidepressant dose was systematically increased in each subject until a therapy effect occurred, between-subjects variability of receptor occupancy might have been small in the included patients despite considerable between-subjects variability of the dose.

Limitations of the current study include the rather small sample size and its retrospective nature. The latter explains that a reference diagnosis was available in only half of the included patients.

In conclusion, withdrawal before [¹²³I]FP-CIT-SPECT should be preferred not only for bupropion but also for venlafaxine. However, if withdrawal is not justifiable or when the treatment was recognized only after the SPECT examination, interpretation of [¹²³I]FP-CIT-SPECT regarding nigrostriatal degeneration is feasible, especially in case of suspected PD.

Funding: The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Competing Interests: The authors have no relevant financial or non-financial interests to disclose.

Author Contributions: All authors contributed to the study conception and design as well as to data collection. The analyses were performed by Ivayla Apostolova, Sabine Hellwig, Philipp T. Meyer and Ralph Buchert. The first draft of the manuscript was written by Ivayla Apostolova, Sabine Hellwig, Philipp T. Meyer and Ralph Buchert. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data Availability: Clinical data (age, sex, venlafaxine and bupropion dose) and z-scores derived from the [¹²³I]FP-CIT-SPECT images are available from the corresponding author on reasonable request.

Ethics approval / Consent to participate:Waiver of informed consent for the retrospective analysis of anonymized data was obtained from the ethics review board of the general medical council of the state of Hamburg, Germany. All procedures performed in this study were in accordance with the ethical standards of the ethics review board of the general medical council of the state of Hamburg, Germany, and with the 1964 Helsinki declaration and its later amendments.

Frisina PG, Borod JC, Foldi NS, Tenenbaum HR. Depression in Parkinson's disease: health risks, etiology, and treatment options. Neuropsychiatr Dis Treat. 2008;4:81–91. 10.2147/ndt.s1453.
Chahid Y, Sheikh ZH, Mitropoulos M, Booij J. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [(123)I]I-FP-CIT SPECT in routine practice. Eur J Nucl Med Mol Imaging. 2023;50:1974–87. 10.1007/s00259-023-06171-x.
Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27:71–5. 10.1097/JCP.0b013e31802e0017.
Kanani M-K, Gurunathan N. Misdiagnosis of dementia with Lewy bodies due to venlafaxine. Progress Neurol Psychiatry. 2022;26:8–10. https://doi.org/10.1002/pnp.742.
Hsiao MC, Lin KJ, Liu CY, Schatz DB. The interaction between dopamine transporter function, gender differences, and possible laterality in depression. Psychiatry Res. 2013;211:72–7. 10.1016/j.pscychresns.2012.06.004.
Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163:102–5. 10.1007/s00213-002-1166-3.
Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47:1885–912. 10.1007/s00259-020-04817-8.
Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, et al. [Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCANTM)]. Nuklearmedizin. 2019;58:5–16. 10.1055/a-0807-8137.
Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87:195–203. 10.1159/000491524.
Buchert R, Szabo B, Kovacs A, Buddenkotte T, Mathies F, Karimzadeh A, et al. Dopamine Transporter SPECT with 12-Minute Scan Duration Using Multiple-Pinhole Collimators. J Nucl Med. 2024;65:446–52. 10.2967/jnumed.123.266276.
Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–58. 10.1016/S0014-2999(97)01393-9.
Mizuno Y, Ashok AH, Bhat BB, Jauhar S, Howes OD. Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies. J Psychopharmacol. 2023;37:1058–69. doi:Artn 0269881123120088110.1177/02698811231200881.

Supplementaryinformation.docx

Download PDF

Reviewers agreed at journal
01 Aug, 2024
Reviewers invited by journal
28 Jul, 2024
Editor assigned by journal
08 Jul, 2024
First submitted to journal
07 Jul, 2024

You are reading this latest preprint version

Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine and bupropion

Status:

Version 1

Abstract

Purpose

Methods

Results

Conclusion

Figures

Introduction

Materials and methods

Patients

SPECT imaging

Semi-quantitative analyses

Statistical analysis

Results

Discussion

Declarations

References

Supplementary Files

Status:

Version 1